Home / Uncategorized / New melanoma drug Zelboraf may double patients’ survival

New melanoma drug Zelboraf may double patients’ survival

People with metastatic melanoma often live six to ten months; new drug prolonged life expectancy to 16 months

Continue reading here:
New melanoma drug Zelboraf may double patients’ survival

If you enjoyed this post, make sure you subscribe to my RSS feed!

About Philippe Matthews

Scroll To Top